retatrutide investigational drug triple hormone receptor agonist Today, we shared new data from two Phase 3 trials of retatrutide, our agonist. Learn more at our link in bio Retatrutide | GLP-1R/GIPR/GCGR ligand |

If someone living with obesity reverses their condition, they may no longer be eligible for health cover and so they, too, will come off the drug

Sterile techniques and certified products reduce these risks significantly

Its the receptor that drives hepatic fat oxidation, raised resting metabolic rate, and the heart-rate cost that comes with higher doses

There is no universal endpoint, the right answer is determined in ongoing consultation with your provider

Jerry Avorn, the author of Rethinking Medications: Truth, Power, and the Drugs You Take , the unregulated nature of supplements means it can be hard to ensure that they are both safe and effective